CAMP4 THERAPEUTICS CORPORATION (CAMP) - Total Assets
Based on the latest financial reports, CAMP4 THERAPEUTICS CORPORATION (CAMP) holds total assets worth $105.46 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CAMP cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CAMP4 THERAPEUTICS CORPORATION - Total Assets Trend (1985–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's total assets have evolved over time, based on quarterly financial data. Check CAMP cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CAMP4 THERAPEUTICS CORPORATION - Asset Composition Analysis
Current Asset Composition (December 2025)
CAMP4 THERAPEUTICS CORPORATION's total assets of $105.46 Million consist of 96.9% current assets and 3.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.0% |
| Accounts Receivable | $155.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1985–2025)
This chart illustrates how CAMP4 THERAPEUTICS CORPORATION's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CAMP4 THERAPEUTICS CORPORATION market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CAMP4 THERAPEUTICS CORPORATION's current assets represent 96.9% of total assets in 2025, an increase from 44.6% in 1985.
- Cash Position: Cash and equivalents constituted 93.0% of total assets in 2025, up from 1.0% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1985.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
CAMP4 THERAPEUTICS CORPORATION Competitors by Total Assets
Key competitors of CAMP4 THERAPEUTICS CORPORATION based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
|
China | CN¥8.41 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653
|
China | CN¥964.85 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
CAMP4 THERAPEUTICS CORPORATION - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.15 | 8.02 | 2.12 |
| Quick Ratio | 6.15 | 8.02 | 1.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $85.57 Million | $45.23 Million | $107.50 Million |
CAMP4 THERAPEUTICS CORPORATION - Advanced Valuation Insights
This section examines the relationship between CAMP4 THERAPEUTICS CORPORATION's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.49 |
| Latest Market Cap to Assets Ratio | 1.85 |
| Asset Growth Rate (YoY) | 50.4% |
| Total Assets | $117.81 Million |
| Market Capitalization | $218.09 Million USD |
Valuation Analysis
Above Book Valuation: The market values CAMP4 THERAPEUTICS CORPORATION's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: CAMP4 THERAPEUTICS CORPORATION's assets grew by 50.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CAMP4 THERAPEUTICS CORPORATION (1985–2025)
The table below shows the annual total assets of CAMP4 THERAPEUTICS CORPORATION from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $117.81 Million | +50.44% |
| 2024-12-31 | $78.31 Million | +42.52% |
| 2023-12-31 | $54.95 Million | -46.42% |
| 2022-12-31 | $102.55 Million | -74.51% |
| 2021-12-31 | $402.29 Million | -8.95% |
| 2020-12-31 | $441.82 Million | -10.89% |
| 2019-12-31 | $495.81 Million | -17.86% |
| 2018-12-31 | $603.63 Million | +27.62% |
| 2017-12-31 | $472.99 Million | +16.02% |
| 2016-12-31 | $407.67 Million | +6.06% |
| 2015-12-31 | $384.36 Million | +89.70% |
| 2014-12-31 | $202.62 Million | +13.03% |
| 2013-12-31 | $179.26 Million | +18.90% |
| 2012-12-31 | $150.77 Million | +192.87% |
| 2011-12-31 | $51.48 Million | -7.22% |
| 2010-12-31 | $55.48 Million | -2.58% |
| 2009-12-31 | $56.95 Million | -18.23% |
| 2008-12-31 | $69.65 Million | -51.31% |
| 2007-12-31 | $143.04 Million | -37.73% |
| 2006-12-31 | $229.70 Million | +12.41% |
| 2005-12-31 | $204.35 Million | +3.86% |
| 2004-12-31 | $196.75 Million | +101.51% |
| 2003-12-31 | $97.64 Million | +8.98% |
| 2002-12-31 | $89.60 Million | +58.05% |
| 2001-12-31 | $56.69 Million | +13.80% |
| 2000-12-31 | $49.81 Million | -10.33% |
| 1999-12-31 | $55.55 Million | +117.85% |
| 1998-12-31 | $25.50 Million | -8.27% |
| 1997-12-31 | $27.80 Million | -5.76% |
| 1996-12-31 | $29.50 Million | -9.51% |
| 1995-12-31 | $32.60 Million | +47.51% |
| 1994-12-31 | $22.10 Million | +12.76% |
| 1993-12-31 | $19.60 Million | +22.50% |
| 1992-12-31 | $16.00 Million | +75.82% |
| 1991-12-31 | $9.10 Million | +89.58% |
| 1990-12-31 | $4.80 Million | -18.64% |
| 1989-12-31 | $5.90 Million | +28.26% |
| 1988-12-31 | $4.60 Million | -39.47% |
| 1987-12-31 | $7.60 Million | +7.04% |
| 1986-12-31 | $7.10 Million | -29.70% |
| 1985-12-31 | $10.10 Million | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more